Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 8/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.75 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.75 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.75 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.75 |
| ▸ | PLK4 | O00444 | 1/20 | 0.75 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.75 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.75 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.75 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.75 |
| ▸ | STK16 | O75716 | 1/20 | 0.75 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.75 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.75 |
| ▸ | NQO2 | P16083 | 1/20 | 0.75 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.75 |
| ▸ | JAK1 | P23458 | 1/20 | 0.75 |
| ▸ | TYK2 | P29597 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190381 | 0.89 | PIK3CA (0.80) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL190889 | 0.88 | PIK3CA (0.79) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL24099901 | 0.87 | PIK3CA (0.78) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| Pictilisib SCHEMBL190812 | 0.86 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| Pictilisib SCHEMBL29387739 | 0.86 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| Pictilisib SCHEMBL14859338 | 0.86 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| Pictilisib SCHEMBL29375636 | 0.86 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL19142475 | 0.85 | PIK3CA (0.73) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL1859631 | 0.85 | PIK3CA (0.73) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL190513 | 0.84 | PIK3CA (0.95) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | claimed |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | claimed |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-16 | — | — | US | claimed |
| EP-2402347-A1 | Pharmaceutical compounds | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | claimed |
| EP-2041139-B1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2011-11-09 | — | — | EP | claimed |
| EP-2041139-A2 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-01 | — | — | EP | claimed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | claimed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | claimed |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2021252895-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| EP-2041139-B1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2011-11-09 | — | — | EP | disclosed |
| EP-2041139-A2 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | TARDBP, PIKFYVE, FUS | PIK3CA 252/4885PIK3CB 87/4885PIK3CD 93/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CB 3/4885PIK3CD 2/4885 |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885PIK3CB 4/4885PIK3CD 2/4885 |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885PIK3CB 4/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.